Loading
A phase 2 trial of Cisplatin, Carboplatin, Paclitaxel / nab-paclitaxel in cervical cancer and head and neck squamous cell carcinoma, run by AstraZeneca, now recruiting.
Study of Volrustomig as Monotherapy or in Combination With Anti- Cancer Agents in Participants With Advanced/Metastatic Solid Tumors is a phase 2 interventional study registered as NCT06535607 by AstraZeneca, with 257 participants planned, started 2024-08-22 and due to reach its primary completion in 2028-11-30. Interventions recorded: Volrustomig, Cisplatin, Carboplatin, Paclitaxel, 5-FU. Conditions listed: Sub-study 1 Cervical Cancer (Volrustomig Monotherapy), Sub-study 2 Head and Neck Squamous Cell Carcinoma (Volrustomig Monotherapy), Sub-study 3 Head and Neck Squamous Cell Carcinoma (Volrustomig in Combination With Chemotherapy), Sub-study 4 Esophageal Squamous Cell Carcinoma (Volrustomig in Combination With Chemotherapy). No results are recorded here; the registry entry is the source.
Shares FLOT (5-FU, leucovorin, oxaliplatin, docetaxel), Paclitaxel / nab-paclitaxel, Cisplatin, Carboplatin.
Shares FLOT (5-FU, leucovorin, oxaliplatin, docetaxel), Paclitaxel / nab-paclitaxel, Carboplatin, Head and neck squamous cell carcinoma.
Shares Mesothelioma, AstraZeneca, Cisplatin, Carboplatin.
Shares FLOT (5-FU, leucovorin, oxaliplatin, docetaxel), AstraZeneca.
Shares Mesothelioma, Carboplatin.
Shares FLOT (5-FU, leucovorin, oxaliplatin, docetaxel), Cisplatin.
Shares FLOT (5-FU, leucovorin, oxaliplatin, docetaxel), AstraZeneca.